Trademark Overview
On Saturday, January 18, 2025, a trademark application was filed for SYTHEIA with the United States Patent and Trademark Office. The USPTO has given the SYTHEIA trademark a serial number of 99012197. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Wednesday, July 23, 2025. This trademark is owned by OCUGEN, INC.. The SYTHEIA trademark is filed in the Pharmaceutical Products category with the following description:
Gene therapy products, namely, genetically engineered tissues for transplant purposes; Gene therapy products, namely, recombinant adeno-associated virus (rAAV) vector for treating ocular diseases; Gene therapy products, namely, rAAV vector for treating Retinitis Pigmentosa; Gene therapy products, namely, recombinant nucleic acid for treating ocular diseases; Gene therapy products, namely, recombinant nucleic acid for treating Retinitis Pigmentosa; Gene therapy products, namely, recombinant DNA for treating ocular diseases; Gene therapy products, namely, recombinant DNA for treating Retinitis Pigmentosa; Gene therapy products, namely, rAAV for treating ocular diseases such as Leber congenital amaurosis (LCA), retinitis pigmentosa, enhance S-cone syndrome, Goldmann Favre syndrome, rod-cone dystrophy Bardet-Biedl Syndrome, Achromatopsia, Best Disease (vitelliform macular degeneration), Bardet-Biedl Syndrome, Choroideremia, Macular Degeneration, Stargardt Disease, X-Linked Retinoschisis (X...
